Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III, INAVO120 primary analysis - Jhaveri, K; Im, S-A; Saura, C (Proceedings of the 2023 San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 2023)